EANM position paper on the role of radiobiology in nuclear medicine
Aerts, A., Eberlein, U., Holm, S. et al. EANM position [...]
PSMA theranostic Lu-177-PSMA-617 approaches prime time in mCRPC
Urology Times Journal, Jason M. Broderick - April 15, 2021 [...]
Noble Registry – iPSMA SPECT Imaging for Prostate Cancer
BRUSSELS, Belgium and MELBOURNE, Australia, 20th of April 2021 – [...]
Evolving role of Ac-225-PSMA Radioligand Therapy in mCRPC
225Ac-PSMA RLT is an efficacious and safe treatment option for [...]
How PRRT can Improve Care for Neuroendocrine Tumor Patients
Learn more about how Peptide Receptor Radionuclide Therapy (PRRT) can [...]
Real-world data analysis of efficacy and survival after Lu-177 PSMA
177Lu-PSMA radioligand therapy provides a significant response rate with a [...]
PSMA Lu-177 x Ac-225
Available since 2015, the treatment of patients with metastatic castration-resistant [...]
Joint Radionuclide Therapy-Immunotherapy Approach Effective in Prostate Cancer Model
Joint radionuclide therapy and immunotherapy approach. The combination shows promising [...]
NET Patient Testimonial, how PRRT saved Tom’s life
Tom is a composer, pianist, audio producer and neuroendocrine tumor patient. [...]
Diagnostic accuracy of F-18-PSMA-1007-PET/CT imaging for prostate carcinoma
J. Nucl. Me. 2020 Aug 17 18F-PSMA-1007-PET/CT reliably detects malignant [...]